Richard Carvajal
MD
Director, Melanoma Program
👥Biography 个人简介
Richard Carvajal is the foremost clinical researcher in uveal melanoma and led the IMCgp100-202 trial establishing tebentafusp as the first systemic therapy to show an overall survival benefit in any uveal melanoma population. His work has characterized the unique biology of GNAQ/GNA11-mutant uveal melanoma, its liver tropism, and the limited activity of conventional checkpoint inhibitors in this distinct entity.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Richard Carvajal 的研究动态
Follow Richard Carvajal's research updates
留下邮箱，当我们发布与 Richard Carvajal（Columbia University Irving Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment